Xenon is focused on advancing our ion channel neurology pipeline.
The products within our novel proprietary pipeline – including XEN496, XEN1101 and XEN007 – are aimed at treating neurological disorders, with a particular focus on epilepsy. We intend to pursue a variety of development strategies, such as those focused on using a “precision medicine” approach to address rare pediatric disorders, including KCNQ2 epilepsy, as well as those targeting broader patient populations, such as adult patients with focal epilepsy. We also have promising partnered products within our pipeline, such as NBI-921352 with Neurocrine Biosciences and FX301 with Flexion Therapeutics.
X-TOLE Clinical Trial
Collaboration with Mount Sinai
EPIK Clinical Trial
for Orphan Neurological Indications
Investigator-led Study in CAE
Partnered with Neurocrine Biosciences
for Post-Operative Pain
Partnered with Flexion Therapeutics
Partnered with Genentech
* A physician-led, Phase 2 proof-of-concept study is ongoing to examine XEN007 as an adjunctive treatment in pediatric patients diagnosed with treatment-resistant childhood absence epilepsy (CAE).